Pharmacokinetics of cefpirome in pediatric patients.

AUTOR(ES)

Nahata, M C

RESUMO

Cefpirome is a new investigational cephalosporin. We designed a study to determine the pharmacokinetics and tolerance of cefpirome in pediatric patients. A single dose of cefpirome was administered intravenously over 15 min to 18 patients (age 0.5 to 18 years). The doses were 10 mg/kg of body weight for five patients, 25 mg/kg of body weight for seven patients, and 50 mg/kg of body weight for six patients. Blood samples were collected at 0, 0.25, 0.5, 1, 3, 5, and 8 h after the dose, and cefpirome was measured by a high-performance liquid chromatography method. The maximum concentration in serum ranged from about 53.6 to 454 micrograms/ml after doses of 10 to 50 mg/kg. The total body clearance, apparent volume of distribution, and elimination half-life were 2.15 +/- 0.70 ml/min/kg, 0.32 +/- 0.32 liter/kg, and 1.8 +/- 1.3 h, respectively. No significant adverse effects were attributed to cefpirome. These data may be useful in conducting efficacy and safety studies of cefpirome in pediatric patients.

Documentos Relacionados

• Piperacillin pharmacokinetics in pediatric patients.
• Pharmacokinetics of teicoplanin in pediatric patients.
• Mezlocillin pharmacokinetics in pediatric oncology patients.
• Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
• Single-dose pharmacokinetics of aztreonam in pediatric patients.